In Sierra Leone, analysis of clinical samples from suspected Lassa fever cases showed that about two-thirds of the patients had been exposed to other emerging diseases and nearly 9 percent tested positive for Ebola virus.
The study, published in this month's edition of Emerging Infectious Diseases, demonstrates that Ebola virus has been circulating in the region since at least 2006—well before the current outbreak.
AdvertisementFirst author Randal J. Schoepp, Ph.D., recently returned from Liberia and Sierra Leone, where he spent six weeks helping to set up an Ebola testing laboratory and training local personnel to run diagnostic tests on suspected Ebola hemorrhagic fever clinical samples. He is part of a team from the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) that has been providing assistance to the Ebola outbreak in West Africa since March.
Three other USAMRIID personnel also have been involved in this ongoing effort: Wes Carter, who traveled with Schoepp to Liberia; Aileen O'Hearn, Ph.D., who recently returned from providing laboratory support to Kenema Government Hospital (KGH) in Sierra Leone; and Matthew Voorhees, who is currently onsite at KGH.
USAMRIID has been working in the region since 2006, when it began a collaborative project to develop and refine diagnostic tests for the Lassa fever virus endemic to Sierra Leone, Liberia and Guinea. As those assays have matured, the scientists have begun to optimize additional tests for a number of emerging diseases.
Because the team was working on disease identification and diagnostics, and had pre-positioned assays in the region, said Schoepp, "We had people on hand who were already evaluating samples and volunteered to start testing right away when the current Ebola outbreak started."
According to the publication's authors, between 500 and 700 samples are submitted each year to the KGH Lassa Diagnostic Laboratory in Sierra Leone. Generally, only 30 to 40 percent of the samples test positive for Lassa fever, so the aim of this study was to determine which other viruses had been causing serious illnesses in the region.
Using assays developed at USAMRIID that detects the presence of IgM, an early protein produced by the body to ward off infection, the research team found evidence of dengue fever, West Nile, yellow fever, Rift Valley fever, chikungunya, Ebola, and Marburg viruses in the samples collected between 2006 and 2008.
In addition, of the samples that tested positive for Ebola, the vast majority reacted to the Zaire strain, which was unexpected, according to the authors.
"Prior to the current outbreak, only one case of Ebola had ever been officially reported in this region, and it was from the Ivory Coast strain," said Schoepp. "We were surprised to see that Zaire—or a variant of Zaire—was causing infection in West Africa several years ago."
The laboratory testing site in Kenema is supported by the Armed Forces Health Surveillance Center-Global Emerging Infections Surveillance and Response System. In collaboration with the host country, the site enables collection of samples that can be used in research toward new medical countermeasures, and allows USAMRIID to evaluate the performance of previously developed laboratory tests using samples collected on-site. The Institute hopes to eventually obtain viral isolates for medical countermeasure development and receive data on the performance of the diagnostic assays.
In addition to providing laboratory testing and training support for the current outbreak, USAMRIID has provided more than 10,000 Ebola assays to support laboratory capabilities in Sierra Leone and Liberia. The Institute also supplied personal protective equipment to Metabiota Inc., a non-government organization (NGO) involved in the testing.
Other contributors to the work include the Department of Defense Joint Program Executive Office-Critical Reagents Program, the Defense Threat Reduction Agency (DTRA) Cooperative Biological Engagement Program, and the DTRA Joint Science and Technology Office.
COL Erin P. Edgar, commander of USAMRIID, called the project "a great example of medical diplomacy at work."
"This collaboration allows USAMRIID to bring our expertise to bear in responding to an international health crisis," he said. "In addition, it enables us to test the medical diagnostics that we develop in a real-world setting where these diseases naturally occur."
USAMRIID's mission is to protect the warfighter from biological threats and to be prepared to investigate disease outbreaks or threats to public health. Research conducted at USAMRIID leads to medical solutions—vaccines, drugs, diagnostics, and information—that benefit both military personnel and civilians. The Institute plays a key role as the lead military medical research laboratory for the Defense Threat Reduction Agency's Joint Science and Technology Office for Chemical and Biological Defense. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.
You May Also Like